Thyroid-stimulating hormone, thyroid hormones, and bone loss

Current Osteoporosis Reports

Volumn 7, Issue 2, 2009, Pages 47-52

  Zaidi, Mone ^a   Davies, Terry F ^a   Zallone, Alberta ^a   Blair, Harry C ^a   Iqbal, Jameel ^a   Moonga, Surinder S ^a   Mechanick, Jeffrey ^a   Sun, Li ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; FOLLITROPIN; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2;

BONE DENSITY; BONE MASS; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; ENZYME INHIBITION; HORMONE ACTION; HORMONE DEFICIENCY; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS FUNCTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SIDE EFFECT; THYROID DISEASE; THYROTROPIN BLOOD LEVEL;

ANIMALS; HUMANS; HYPERTHYROIDISM; MICE; MODELS, ANIMAL; OSTEOGENESIS; OSTEOPOROSIS; THYROID HORMONES; THYROTOXICOSIS; THYROTROPIN;

EID: 70349739385     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-009-0009-0     Document Type: Review

References (46)

1. Stepnick LS: The frequency of bone disease. In Bone Health and Osteoporosis: A Report of the Surgeon General. Edited by McGowan JA, Raisz LG, Noonan AS, Elderkin AL. Washington, DC: Office of the US Surgeon General; 2004:68-87.
2. Greenspan SL, Greenspan FS: The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999, 130:750-758.
3. Von Recklinghausen F: Die Fibrose Oder Deformierende Ostitis, die Osteomalazie und die Osteoplastische Carzinose in Ihren Gegenseitigen Beziehungen. Berlin: George Reimer; 1891.
4. Ross DS: Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994, 4:319-326.
5. Baran DT: Thyroid hormoneTand bone mass: the clinician's dilemma. Thyroid 1994, 4:143-144.
6. Murphy E, Williams GR: The thyroid and the skeleton. Clin Endocr 2004, 61:285-298.
7. Wenzel KW: Thyroid hormone and bone. Thyroid 1994, 4:508-509.
8. Allain TJ, Chambers TJ, Flanagan AM, McGregor AM: Tri-iodothyronine stimulates rat osteoclastic bone resorption by an indirect effect. J Endocrinol 1992, 133:327-331.
9. Britto JM, Fenton AJ, Holloway WR, Nicholson GC: Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134:169-176.
10. Kim CH, Kim HK, Shong YK, et al.: Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: A possible mediator of thyroid hormone-induced bone loss. J Endocrinol 1999, 160:97-102.
11. Ishikawa Y, Genge BR, Wuthier RE, Wu LN.: Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. J Bone Miner Res 1998, 13:1398-1411.
12. Bassett JH, Nordström K, Boyde A, et al.: Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol 2007, 21:1893-1904.
13. De Menis E, Da Rin G, Roiter I, et al.: Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 1992, 37:217-220.
14. Kisakol G, Kaya A, Gonen S, Tunc R: Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003, 50:657-661.
15. Földes J, Tarján G, Szathmari M, et al.: Bone mineral density in patients with endogenous subclinical hyperthyroidism: Is this thyroid status a risk factor for osteoporosis? Clin Endocr 1993, 39:521-527.
16. Gurlek A, Gedik O: Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999, 9:539-543.
17. Kindblom JM, Gevers EF, Skrtic SM, et al.: Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 2005, 36:607-616.
18. Göthe S, Wang Z, Ng L, et al.: Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 1999, 13:1329-1341.
19. Bauer DC, Ettinger B, Nevitt MC, et al.: Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001, 134:561-568.
20. Morris MS: The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007, 40:1128-1134.
21. Bassett JH, O'shea PJ, Sriskantharajah S, et al.: Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007, 21:1095-1107.
22. Bassett D, Williams G: The skeletal phenotypes of TRalpha and TRbeta mutant mice. J Mol Endocrinol 2008 Dec 29 (Epub ahead of print).
23. Abe E, Marians RC, Yu W, et al.: TSH is a negative regulator of skeletal remodeling. Cell 2003, 115:151-162.
24. Novack D: TSH, the bone suppressing hormone. Cell 2003, 115:129-130.
25. Zaidi M, Sun L, DaviesFTF, Abe E: Low TSH triggers bone loss: fact or fiction? Thyroid 2006, 16:1075-1076.
26. Hase H, Ando T, Eldeiry L, et al.: TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A 2006, 103:12849-12854.
27. Sun L, Vukicevic S, Baliram R, et al.: Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 2008, 105:4289-4294.
28. Yamoah K, Brebene A, Baliram R, et al.: High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol 2008, 22:1141-1153.
29. Ma R, Latif R, Zaidi M, Davies T: Thyroid and bone: TSH inhibits osteoclastogenesis from embryonic stem cells. Presented at the 91st Annual Meeting of the Endocrine Society. Washington DC; June 10-13, 2009.
30. Bassett JH, Williams AJ, Murphy E, et al.: A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 2008, 22:501-512.
31. Mazziotti G, Sorvillo F, Piscopo M, et al.: Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma J Bone Miner Res 2005, 20:480-486.
32. Sampath TK, Simic P, Sendak R, et al.: Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 2007, 22:849-859.
33. Giusti M, Cecoli F, Ghiara C, et al.: Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens) 2007, 6:304-313.
34. Martini G, Gennari L, De Paola V, et al.: The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 2008, 18:455-460.
35. Zofkova I, Hill M: Biochemical markers of bone remodeling correlate negatively with circulating TSH in postmenopausal women. Endocr Regul 2008, 42:121-127.
36. La Vignera S, Vicari E, Tumino S, et al.: L-thyroxin treatment and post-menopausal osteoporosis: Relevance of the risk profile present in clinical history. Minerva Ginecol 2008, 60:475-484.
37. Grimnes G, Emaus N, Joakimsen RM, et al.: The relationship between serum TSH and bone mineral density in men and postmenopausal women: The Troms. Thyroid 2008, 18:1147-1155.
38. Mikosch P, Kerschan-Schindl K, Woloszczuk W, et al.: High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 2008, 18:27-33.
39. Heemstra KA, van der Deure WM, Peeters RP, et al.: Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. Eur J Endocrinol 2008, 159:69-76.
40. Nagata M, Suzuki A, Sekiguchi S, et al.: Subclinical hypothyroidism is related to lower heel QUS in postmenopausal women. Endocr J 2007, 54:625-630.
41. van der Deure WM, Uitterlinden AG, Hofman A, et al.: Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: The Rotterdam Study. Clin Endocrinol (Oxf) 2008, 68:175-181.
42. Albagha OME, Natarajan R, Reid DM, et al.: The D272E polymorphism of the human thyroid stimulating hormone receptor is associated with bone mineral density and bone loss in women from the UK [abstract M115]. J Bone Miner Res 2005, 20(Suppl 1):S341.
43. Sun L, Peng Y, Sharrow AC, et al.: FSH directly regulates bone mass. Cell 2006, 125:247-260.
44. Iqbal J, Sun L, Kumar TR, et al.: Follicle stimulating hormone stimulates TNF production from immune cells to trigger osteoclast and osteoblast formation. Proc Natl Acad Sci U S A 2006, 103:14925-14930.
45. Sowers MR, Greendale GA, Bondarenko I, et al.: Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003, 14:191-197.
46. Devleta B, Adem B, Senada SJ: Hypergonadotropic amenorrhea and bone density: New approach to an old problem. Bone Miner Metab 2004, 22:360-364.